Gebski VCHIH-HSIN YANGLee C.K.2020-05-262020-05-2620182374-2437https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051421682&doi=10.1001%2fjamaoncol.2018.1105&partnerID=40&md5=47cc6da92dad9e7afa0375cdd944d23ahttps://scholars.lib.ntu.edu.tw/handle/123456789/494912[SDGs]SDG3pembrolizumab; cancer immunotherapy; cancer mortality; human; Letter; meta analysis (topic); probability; survival rate; survival time; lung tumor; non small cell lung cancer; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasmsletter10.1001/jamaoncol.2018.1105299312172-s2.0-85051421682